BG103439A - Therapeutical and diagnostical forms - Google Patents
Therapeutical and diagnostical formsInfo
- Publication number
- BG103439A BG103439A BG103439A BG10343999A BG103439A BG 103439 A BG103439 A BG 103439A BG 103439 A BG103439 A BG 103439A BG 10343999 A BG10343999 A BG 10343999A BG 103439 A BG103439 A BG 103439A
- Authority
- BG
- Bulgaria
- Prior art keywords
- diagnostical
- therapeutical
- forms
- gas
- reporter
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 239000000463 material Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 238000002604 ultrasonography Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9622366.4A GB9622366D0 (en) | 1996-10-28 | 1996-10-28 | Improvements in or relating to diagnostic/therapeutic agents |
GBGB9622369.8A GB9622369D0 (en) | 1996-10-28 | 1996-10-28 | Improvements in or relating to diagnostic/therapeutic agents |
GBGB9702195.0A GB9702195D0 (en) | 1997-02-04 | 1997-02-04 | Improvements in or relating to diagnostic/therapeutic agents |
GBGB9708265.5A GB9708265D0 (en) | 1997-04-24 | 1997-04-24 | Contrast agents |
US4926397P | 1997-06-06 | 1997-06-06 | |
US4926697P | 1997-06-06 | 1997-06-06 | |
US4926497P | 1997-06-06 | 1997-06-06 | |
GBGB9711837.6A GB9711837D0 (en) | 1997-06-06 | 1997-06-06 | Improvements in or relating to diagnostic / therapeutic agents |
GBGB9711839.2A GB9711839D0 (en) | 1997-06-06 | 1997-06-06 | Improvements in or relating to diagnostic/therapeutic agents |
PCT/GB1997/002953 WO1998018500A2 (en) | 1996-10-28 | 1997-10-28 | Improvements in or relating to diagnostic/therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BG103439A true BG103439A (en) | 2000-01-31 |
Family
ID=27576371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG103439A BG103439A (en) | 1996-10-28 | 1999-05-27 | Therapeutical and diagnostical forms |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1007101B1 (no) |
JP (1) | JP2001511765A (no) |
KR (1) | KR20000052830A (no) |
CN (1) | CN1238700A (no) |
AT (1) | ATE326242T1 (no) |
AU (1) | AU733477B2 (no) |
BG (1) | BG103439A (no) |
BR (1) | BR9713978A (no) |
CA (1) | CA2269985A1 (no) |
DE (1) | DE69735901T2 (no) |
HU (1) | HUP0000357A2 (no) |
IL (1) | IL129445A0 (no) |
NO (1) | NO991890L (no) |
NZ (1) | NZ335799A (no) |
WO (1) | WO1998018500A2 (no) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9711082A (pt) | 1996-03-29 | 2000-01-11 | Lawrence Berkeley National Lab | Realce de rmn emri na presença de gases mopbres hiperpolarizados. |
US5846517A (en) * | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
ATE265525T1 (de) * | 1998-04-28 | 2004-05-15 | Amersham Health As | Verbesserung von trennungsverfahren |
GB9917111D0 (en) | 1999-07-21 | 1999-09-22 | Nycomed Imaging As | Method |
US7109167B2 (en) | 2000-06-02 | 2006-09-19 | Bracco International B.V. | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
US8263739B2 (en) | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
US7061237B2 (en) | 2000-07-13 | 2006-06-13 | The Regents Of The University Of California | Remote NMR/MRI detection of laser polarized gases |
US6652833B2 (en) * | 2000-07-13 | 2003-11-25 | The Regents Of The University Of California | Functionalized active-nucleus complex sensor |
US6679822B2 (en) | 2001-03-02 | 2004-01-20 | Nof Corporation | Polyalkylene oxide-modified phospholipid and production method thereof |
US20050100963A1 (en) | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
US7666979B2 (en) | 2002-03-01 | 2010-02-23 | Bracco International B.V. | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
AU2003300133B2 (en) | 2002-12-31 | 2008-11-13 | Nektar Therapeutics | Hydrolytically stable maleimide-terminated polymers |
US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
CA2512454C (en) | 2003-02-04 | 2012-10-30 | Bracco Research Sa | Ultrasound contrast agents and process for the preparation thereof |
CA2545362C (en) * | 2003-12-22 | 2013-02-12 | Bracco Research Sa | Assembly of gas-filled microvesicle with active component for contrast imaging |
CA2547024C (en) * | 2003-12-22 | 2013-12-17 | Bracco Research Sa | Gas-filled microvesicle assembly for contrast imaging |
DE602005017475D1 (de) | 2004-03-04 | 2009-12-17 | Ge Healthcare As | Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie |
EP1784228B1 (en) | 2004-08-18 | 2016-10-05 | Bracco Suisse SA | Gas-filled microvesicles composition for contrast imaging |
RU2007118385A (ru) | 2004-11-22 | 2008-12-27 | Джи-И Хелткер АС (NO) | Контрастные агенты для направлений доставки во внеклеточный матрикс |
JP2006182673A (ja) * | 2004-12-27 | 2006-07-13 | Kenji Yamamoto | マーカー付き医薬 |
WO2008075968A1 (en) * | 2006-12-20 | 2008-06-26 | Ge Healthcare As | Contrast agents |
CN101773675B (zh) * | 2010-03-05 | 2012-05-30 | 中山大学 | 一种负载液态氟碳的聚合物纳米超声显像囊泡及其制备方法 |
US20130072854A1 (en) * | 2011-09-19 | 2013-03-21 | General Electric Company | Microbubble complexes and methods of use |
WO2014117232A1 (pt) * | 2013-02-04 | 2014-08-07 | Farret Neto Abdo | Preparação medicinal sob a forma de espuma para a liberação prolongada de medicamentos e sistema para obtenção da preparação medicinal |
EP3177904A4 (en) * | 2014-08-07 | 2018-01-03 | The General Hospital Corporation | Platelet-targeted microfluidic isolation of cells |
CN113289034A (zh) | 2014-12-31 | 2021-08-24 | 蓝瑟斯医学影像公司 | 脂质封装的气体微球组合物及相关方法 |
IL262647B2 (en) | 2016-05-04 | 2023-03-01 | Lantheus Medical Imaging Inc | Methods and devices for preparing sharpness factors for ultrasound |
US9789210B1 (en) | 2016-07-06 | 2017-10-17 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
CN116223678A (zh) * | 2023-03-09 | 2023-06-06 | 石家庄四药有限公司 | 一种测定血液中依托咪酯的方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN172208B (no) * | 1990-04-02 | 1993-05-01 | Sint Sa | |
US5780010A (en) * | 1995-06-08 | 1998-07-14 | Barnes-Jewish Hospital | Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system |
US5849727A (en) * | 1996-06-28 | 1998-12-15 | Board Of Regents Of The University Of Nebraska | Compositions and methods for altering the biodistribution of biological agents |
-
1997
- 1997-10-28 HU HU0000357A patent/HUP0000357A2/hu unknown
- 1997-10-28 AU AU47182/97A patent/AU733477B2/en not_active Ceased
- 1997-10-28 WO PCT/GB1997/002953 patent/WO1998018500A2/en active IP Right Grant
- 1997-10-28 CA CA002269985A patent/CA2269985A1/en not_active Abandoned
- 1997-10-28 CN CN97180164A patent/CN1238700A/zh active Pending
- 1997-10-28 DE DE69735901T patent/DE69735901T2/de not_active Expired - Fee Related
- 1997-10-28 BR BR9713978-5A patent/BR9713978A/pt unknown
- 1997-10-28 AT AT97909512T patent/ATE326242T1/de not_active IP Right Cessation
- 1997-10-28 EP EP97909512A patent/EP1007101B1/en not_active Expired - Lifetime
- 1997-10-28 KR KR1019990703659A patent/KR20000052830A/ko not_active Application Discontinuation
- 1997-10-28 IL IL12944597A patent/IL129445A0/xx unknown
- 1997-10-28 NZ NZ335799A patent/NZ335799A/xx unknown
- 1997-10-28 JP JP52018698A patent/JP2001511765A/ja not_active Ceased
-
1999
- 1999-04-21 NO NO991890A patent/NO991890L/no not_active Application Discontinuation
- 1999-05-27 BG BG103439A patent/BG103439A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0000357A2 (hu) | 2000-06-28 |
CA2269985A1 (en) | 1998-05-07 |
BR9713978A (pt) | 2000-05-02 |
NO991890L (no) | 1999-06-28 |
CN1238700A (zh) | 1999-12-15 |
EP1007101B1 (en) | 2006-05-17 |
NZ335799A (en) | 2000-11-24 |
DE69735901T2 (de) | 2007-05-10 |
WO1998018500A2 (en) | 1998-05-07 |
JP2001511765A (ja) | 2001-08-14 |
WO1998018500A8 (en) | 1999-11-25 |
EP1007101A2 (en) | 2000-06-14 |
DE69735901D1 (de) | 2006-06-22 |
KR20000052830A (ko) | 2000-08-25 |
AU733477B2 (en) | 2001-05-17 |
NO991890D0 (no) | 1999-04-21 |
IL129445A0 (en) | 2000-02-29 |
AU4718297A (en) | 1998-05-22 |
ATE326242T1 (de) | 2006-06-15 |
WO1998018500A3 (en) | 1998-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG103439A (en) | Therapeutical and diagnostical forms | |
HUT75555A (en) | Lactobacillus strains of human origin, their compositions and uses thereof | |
MX9700223A (es) | Composicion farmaceutica para la liberacion controlada de moguisteina en una suspension liquida. | |
SE9504077D0 (sv) | Vätskeabsorberande artikel ansedd för engångsanvändning | |
DE69839940D1 (de) | Sauerstoff-abgabe mittel und ihre anwendung | |
CA2308513A1 (en) | Method and composition for delivering zinc to the nasal membrane | |
EP0680525A1 (en) | FIBERS. | |
AU2515895A (en) | Gel stick compositions comprising optically enriched gellants | |
MX9707570A (es) | Utilizacion de agonistas de alta1l para el tratamiento de la incontinencia urinaria. | |
MX9704030A (es) | 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos. | |
ATE204297T1 (de) | Peptidanaloge des lh-rh, ihre verwendungen und die sie enthaltenden pharmazeutischen zusammensetzungen | |
WO1998018498A3 (en) | Improvements in or relating to diagnostic/therapeutic agents | |
BR9813817A (pt) | Análogos de hemiasterlina | |
BG103968A (en) | Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity | |
BG103677A (en) | Solid mixtures based on sulphonylcarbamides and adjuvants | |
DE69120287D1 (en) | Aminosulfonylharnstoff-acat-inhibitoren | |
MY112148A (en) | Suspension concentrate compositions of arylpyrrole insecticidal and acarricidal agents | |
BG100248A (en) | Squalene synthetase inhibitors | |
BG103306A (en) | Liquid allendronate compositions | |
ZA934777B (en) | Novel piperidyl amides, sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis. | |
DE3560313D1 (en) | Improvements in or relating to anticonvulsant agents | |
ITBO950012A0 (it) | Integratore liquido per l'arricchimento di concimi e fertilizzanti | |
HU9402648D0 (en) | 3,4-dioxo-1-cyclobuten-1-yl-substituted (indolyl-alkyl)-pyridine- and -pyrimidine derivatives and antimigraine composition containing them as active componens | |
CA2120874A1 (en) | Form 1 ranitidine form | |
CA2125403A1 (en) | Novel tissue plasminogen activator variants |